Romania

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: The surprise resignation of Romanian prime minister Emil Boc and his government on February 6 is very bad news for private healthcare insurers, which just a month ago were... 2012-02-07

BMI View: While there has been no immediate impact on Romania's health system following the withdrawal of the draft healthcare reform bill, the development is bad news for private healthcare... 2012-01-16

BMI View: Corrections to the reintroduced claw-back mechanism in Romania are favourable to drugmakers, but the levy itself is still overly burdensome. In October 2011, we stated that:... 2011-12-07

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: The introduction of a revised claw-back mechanism in Romania has angered drugmakers operating in the market. BMI believes the current form of the legislation is overly simplistic... 2011-10-13

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: The immediate ramifications of the resignation of Romanian Health Minister Attila Czeke are limited, but the development is an illustration of the chronic underfunding within... 2011-08-12

BMI View: We continue to expect Romania's pharmaceutical market to return high single-digit growth in 2011 and 2012. However, weaker than expected drug price inflation in Q211 has resulted... 2011-08-03

BMI View: Our projections that Romania's pharmaceutical market will continue to see high-single-digit growth into 2011 have now been confirmed. However, we continue to highlight risks... 2011-05-11